VIRX - Viracta Therapeutics, Inc.
IEX Last Trade
0.241
-0.007 -2.905%
Share volume: 517
Last Updated: Thu 26 Dec 2024 08:17:58 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.25
-0.01
-2.82%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
7.43%
1 Month
75.32%
3 Months
13.38%
6 Months
-55.36%
1 Year
-53.62%
2 Year
-82.27%
Key data
Stock price
$0.24
DAY RANGE
$0.25 - $0.25
52 WEEK RANGE
$0.15 - $1.31
52 WEEK CHANGE
-$56.16
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Mark A. Rothera
Region: US
Website: viracta.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: viracta.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Viracta Therapeutics, Inc. engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir. The company's development pipeline includesvecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510.
Recent news